Hemoperfusion study for kidney patients on dialysis
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced kidney disease (stage 5) and your kidney function is very low
- You have been on regular hemodialysis for at least 3 months, twice a week for 4 hours each session
- Your blood levels of certain substances (like beta-2 microglobulin or PTH) are high
- You are willing to sign a consent form
- You do not have active bleeding, severe allergies to dialysis materials, or other serious health issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a special blood-cleaning treatment called hemoperfusion to regular dialysis can improve health outcomes for people with kidney failure. It aims to see if this extra treatment helps patients feel better and live longer.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests a long-term, high-flow hemoadsorption therapy for people on maintenance hemodialysis. It aims to see if the treatment can improve outcomes for those with uremia (built-up waste in the blood).
This study tests a special filter called pHA130 that is used during your regular hemodialysis sessions for a full 4 hours. The purpose is to see if it helps improve your dialysis treatment outcomes.
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
This trial tests whether adding a special blood-filtering device (hemoadsorption) to your regular dialysis treatment can reduce uncomfortable symptoms caused by kidney failure, like fatigue or itching. Researchers will track how you feel over time compared to standard dialysis alone.
Hear when a new Uremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.